Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,147
- Phase 21,063
- Phase 1819
- Phase 1/Phase 2442
- Phase 3425
- Phase 4238
- Phase 2/Phase 396
Top conditions
- Multiple Sclerosis343
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis140
- Type 1 Diabetes133
- Atopic Dermatitis129
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Type 1 Diabetes Mellitus63
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)73
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals60
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California491
- Maryland195
- Alabama175
- Florida144
- Arizona142
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT07017907Recruiting
AI tool for detecting thyrotoxic states
This study tests an artificial intelligence tool designed to help detect overactive thyroid conditions (thyrotoxicosis). It may be an option for people with Graves' disease, whether newly diagnosed or currently in treatment.
San Francisco, CaliforniaAges 22 years+ - NCT07018024Recruiting
Study for anti-GBM disease patients
This study looks at people with anti-GBM disease, a rare kidney condition, to learn more about the disease and its treatment. If you were diagnosed between 2010 and 2027, or have stored blood or urine samples from your diagnosis, you might be able to join.
LundAges 18 years+ - NCT07018050RecruitingPhase 2
A study of a new combination for multiple myeloma
This study tests a new combination therapy for people with multiple myeloma that has returned or not responded to at least one prior treatment. The goal is to see if the combination (QLS32015 plus other drugs) can effectively control the cancer.
TianjinAges 18 years+ - NCT07018752RecruitingPhase 1/Phase 2
Testing new drug combos for relapsed T-cell lymphoma
This trial is testing several new drug combinations for people with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to find new options that may work better.
CaenAges 18 years+ - NCT07019038Recruiting
Autoimmune hemolytic anemia long-term study
This study looks at people with autoimmune hemolytic anemia (AIHA) over time. It aims to understand the disease better and find ways to improve care.
Tianjin, Tianjin MunicipalityAges Any age - NCT07019766Recruiting
Long-term study of LGLL leukemia patients
This study follows people with large granular lymphocytic leukemia (LGLL) over time to learn more about the disease. It collects information from patients treated at the Institute of Hematology and Blood Diseases Hospital in China.
Tianjin, Tianjin MunicipalityAges Any age - NCT07019857Recruiting
Thymus removal and immunity in infant heart surgery
This study looks at how removing the thymus gland during infant heart surgery affects the immune system. It compares babies who have their thymus removed with those who have heart surgery without removing it, and with babies having other types of surgery.
NantesAges Up to 6 months - NCT07020819RecruitingPhase 3
Study of tanruprubart for people with Guillain-Barré syndrome
This trial tests a new medicine, tanruprubart (also called ANX005), for people with Guillain-Barré syndrome. It aims to see if the drug can help improve recovery when given soon after symptoms start.
Phoenix, ArizonaAges 12–85 - NCT07021456Recruiting
How diet education affects eating disorder risk in type 1 diabetes
This study looks at how learning about counting carbs and adjusting insulin (called Functional Insulin Therapy) might impact eating habits and the risk of eating disorders in adults with type 1 diabetes.
GrenobleAges 18 years+ - NCT07021495Recruiting
Skin disease study to improve treatment choices
This study looks at different skin diseases to find markers that can help guide treatment. It tests new treatments for several conditions like eczema, psoriasis, and lupus, with the goal of personalizing care.
Nijmegen, GelderlandAges 18 years+ - NCT07021677RecruitingPhase 2
Daratumumab for leftover leukemia cells after T-ALL treatment
This trial tests if adding the drug daratumumab can clear remaining cancer cells in people with T-cell acute lymphoblastic leukemia (T-ALL) who still have a small amount of leukemia after initial chemotherapy. It aims to reduce the risk of the cancer coming back.
Navi Mumbai, MaharashtraAges 18–65 - NCT07022197RecruitingPhase 1/Phase 2
BAFF-R CAR T cells for severe nerve and immune diseases
This trial tests a new treatment using your own immune cells (called BAFF-R CAR T cells) for people with severe nerve and immune diseases that have not improved with standard medicines. These cells are designed to target and destroy certain immune cells that may be causing your illness.
Tianjin, Tianjin MunicipalityAges 18–60 - NCT07022223RecruitingPhase 2
Orelabrutinib plus rituximab for first treatment of marginal zone lymphoma
This trial tests a combination of two targeted drugs, orelabrutinib and rituximab, as the first systemic treatment for marginal zone lymphoma. If you have not yet had chemotherapy for your lymphoma and meet certain health criteria, you may be able to join.
Hangzhou, ZhejiangAges 18 years+ - NCT07022964RecruitingPhase 1/Phase 2
CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma
This trial tests a new treatment called CD5 CAR T-cell therapy for people with T-cell lymphoma that has come back or not responded to standard treatments. It offers a possible option when other therapies like chemotherapy or stem cell transplant are no longer working.
BeijingAges 14–70 - NCT07025005RecruitingPhase 4
Fenofibrate to prevent nerve damage from multiple myeloma treatment
This trial tests if adding fenofibrate to standard treatment (VRd) can prevent nerve damage (peripheral neuropathy) caused by bortezomib in patients with newly diagnosed multiple myeloma. If you are starting VRd therapy, this study may help reduce pain or numbness from the chemotherapy.
Damanhur, El- BehiraAges 18 years+ - NCT07025200Recruiting
Severe asthma study using bronchoscopy to check treatment
This study tests a new way to monitor severe asthma that is driven by high levels of inflammation (T2-high). It involves a bronchoscopy (a thin tube to look inside your lungs) to see how well the treatment is working.
Vienna, State of ViennaAges 18 years+ - NCT07028112Recruiting
Iron and liver health after stem cell transplant
This study looks at how too much iron in the body (from past transfusions) affects the liver in people who had a stem cell transplant at least 10 years ago. It will help doctors understand who needs special monitoring for liver problems.
ParisAges 18 years+ - NCT07028970Recruiting
Long-term follow-up study for equecabtagene autoleucel recipients
This registry study will follow people who have received the CAR T-cell therapy equecabtagene autoleucel to monitor their long-term health and outcomes. It is open to those who completed or withdrew from an earlier study of this treatment.
BeijingAges Any age - NCT07029217RecruitingPhase 3
Lower radiation dose study for B-cell lymphomas
This study tests if a reduced dose of radiation therapy works well for certain types of B-cell lymphomas, specifically follicular lymphoma and marginal zone lymphoma. It aims to minimize side effects while still controlling the disease.
Basking Ridge, New JerseyAges 18 years+ - NCT07029503RecruitingPhase 2
Heart failure and kidney function study
This trial tests a new treatment for people with heart failure and severely reduced kidney function. It aims to see if the treatment can help protect both the heart and kidneys.
StockholmAges 18 years+ - NCT07030400Recruiting
Quality of life study for adults with CLL or SLL
This study looks at how health-related quality of life changes in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when starting a new treatment. The goal is to better understand what affects well-being during therapy.
Tampa, FloridaAges 18 years+ - NCT07030881Recruiting
Spacer use in older adults with COPD or asthma on triple therapy
This trial tests whether using a spacer with your inhaler can lower the risk of serious flare-ups for people over 65 who have COPD or asthma and are already on triple therapy.
Hefei, AnhuiAges 65 years+ - NCT07030894RecruitingPhase 4
Study of Nefecon and Ambrisentan for IgA Nephropathy
This trial tests two medications, Nefecon and Ambrisentan, to see if they can help people with IgA nephropathy, a kidney disease. It may be an option if you have been diagnosed with IgA nephropathy in the last 4 years and have protein in your urine.
Changchun, JilinAges 18–70 - NCT07030920RecruitingPhase 2
Reducing inflammation in people living with HIV
This trial tests if a drug can lower inflammation in people with HIV who are on effective treatment. It may help reduce the risk of heart disease and other problems related to chronic inflammation.
Montreal, QuebecAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,763 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.